EE491 Cost-Effectiveness of paclitaxel Monotherapy Versus paclitaxel Plus Bevacizumab Combination Therapy in Triple-Negative Breast Cancer
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.738
https://www.valueinhealthjournal.com/article/S1098-3015(22)00939-1/fulltext
Title :
EE491 Cost-Effectiveness of paclitaxel Monotherapy Versus paclitaxel Plus Bevacizumab Combination Therapy in Triple-Negative Breast Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00939-1&doi=10.1016/j.jval.2022.04.738
First page :
Section Title :
Open access? :
No
Section Order :
10669